Health Care [ 9/12 ] | Biotechnology [ 37/76 ]
NASDAQ | Common Stock
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 19, 26 | -0.14 Increased by +12.50% | -0.15 Increased by +7.35% |
| Nov 10, 25 | -0.12 Increased by +15.43% | -0.15 Increased by +17.86% |
| Aug 12, 25 | -0.13 Increased by +18.75% | -0.15 Increased by +13.33% |
| May 12, 25 | -0.13 Increased by +18.75% | -0.16 Increased by +18.75% |
| Mar 17, 25 | -0.16 Decreased by -77.78% | -0.15 Decreased by -6.67% |
| Nov 10, 24 | -0.14 Increased by +21.17% | -0.15 Increased by +5.40% |
| Aug 9, 24 | -0.16 Decreased by -14.29% | -0.17 Increased by +5.88% |
| May 10, 24 | -0.16 Increased by 0.00% | -0.18 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 225.00 K Increased by +196.05% | -19.23 M Increased by +9.62% | Decreased by -8.55 K% Increased by +69.47% |
| Sep 30, 25 | 217.00 K Increased by +N/A% | -16.47 M Increased by +8.05% | Decreased by -7.59 K% Decreased by N/A% |
| Jun 30, 25 | 221.00 K Increased by +N/A% | -16.55 M Decreased by -32.35% | Decreased by -7.49 K% Decreased by N/A% |
| Mar 31, 25 | 230.00 K Increased by +N/A% | -16.73 M Decreased by -76.30% | Decreased by -7.28 K% Decreased by N/A% |
| Dec 31, 24 | 76.00 K Decreased by -98.31% | -21.28 M Decreased by -273.23% | Decreased by -28.00 K% Decreased by -21.97 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -17.91 M Decreased by -63.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.51 M Decreased by -37.16% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.49 M Increased by +1.79% | Decreased by N/A% Decreased by N/A% |